Beijing Luzhu Biotechnology Co (HKSE:02480) Operating Margin %: 0.00% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02480 Beijing Luzhu Biotechnology Co Ltd HKSE:02480
24 GF Score
Price HK$13.00
! 3 Warning Signs
View Full Analysis

What is Beijing Luzhu Biotechnology Co Operating Margin %?

Beijing Luzhu Biotechnology Co HKSE:02480 24 Operating Margin % is 0.00% as of Dec. 2025. GuruFocus rates HKSE:02480 with a GF Score™ of 24/100. The stock has 3 warning signs investors should review. Among 940 Biotechnology companies, Beijing Luzhu Biotechnology Co ranks worse than 106382.87% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. Beijing Luzhu Biotechnology Co's Operating Income for the six months ended in Dec. 2025 was HK$-76.83 Mil. Beijing Luzhu Biotechnology Co's Revenue for the six months ended in Dec. 2025 was HK$0.00 Mil. Therefore, Beijing Luzhu Biotechnology Co's Operating Margin % for the quarter that ended in Dec. 2025 was 0.00%.

The historical rank and industry rank for Beijing Luzhu Biotechnology Co's Operating Margin % or its related term are showing as below:


HKSE:02480's Operating Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -86.55
* Ranked among companies with meaningful Operating Margin % only.

Beijing Luzhu Biotechnology Co's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Beijing Luzhu Biotechnology Co's Operating Income for the six months ended in Dec. 2025 was HK$-76.83 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-156.71 Mil.

Warning Sign:

Beijing Luzhu Biotechnology Co Ltd has never been profitable in the past 3 years. It lost money every year.


Beijing Luzhu Biotechnology Co  (HKSE:02480) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Beijing Luzhu Biotechnology Co Operating Margin % Related Terms


Beijing Luzhu Biotechnology Co Operating Margin % Historical Data

* Premium members only.

The historical data trend for Beijing Luzhu Biotechnology Co's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beijing Luzhu Biotechnology Co Operating Margin % Chart

Beijing Luzhu Biotechnology Co Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Operating Margin %
0.00 0.00 0.00 0.00 0.00

Beijing Luzhu Biotechnology Co Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Operating Margin % Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

HKSE:02480 vs VRTX, REGN, ALNY: Operating Margin % Comparison

For the Biotechnology subindustry, Beijing Luzhu Biotechnology Co's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Beijing Luzhu Biotechnology Co Operating Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Beijing Luzhu Biotechnology Co's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Beijing Luzhu Biotechnology Co's Operating Margin % falls into.


HKSE:02480
24GF Score
Beijing Luzhu Biotechnology Co Ltd HKSE:02480
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beijing Luzhu Biotechnology Co Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Beijing Luzhu Biotechnology Co's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (A: Dec. 2025 ) / Revenue (A: Dec. 2025 )
=-157.558 / 0
= %

Beijing Luzhu Biotechnology Co's Operating Margin % for the quarter that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2025 ) / Revenue (Q: Dec. 2025 )
=-76.828 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of 0.00% mean?
Beijing Luzhu Biotechnology Co (HKSE:02480) has a Operating Margin % of 0.00% as of Dec. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on Beijing Luzhu Biotechnology Co and its competitors. According to the industry distribution chart, Beijing Luzhu Biotechnology Co ranks #999999 out of 940 companies in the Biotechnology industry.
Is Beijing Luzhu Biotechnology Co's Operating Margin % too high?
Beijing Luzhu Biotechnology Co's current Operating Margin % is 0.00%. Based on the distribution chart, Beijing Luzhu Biotechnology Co ranks #999999 out of 940 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Beijing Luzhu Biotechnology Co has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Beijing Luzhu Biotechnology Co's Operating Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Beijing Luzhu Biotechnology Co ranks #999999 out of 940 companies for Operating Margin %. This places Beijing Luzhu Biotechnology Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Beijing Luzhu Biotechnology Co and its competitors. Beijing Luzhu Biotechnology Co's current Operating Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Luzhu Biotechnology Co stock overvalued right now?
Beijing Luzhu Biotechnology Co (HKSE:02480) has a current Operating Margin % of 0.00%. The current Operating Margin % is 0.00%. Beijing Luzhu Biotechnology Co's overall GF Score™ is 24/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Beijing Luzhu Biotechnology Co (HKSE:02480), the current Operating Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Beijing Luzhu Biotechnology Co Business Description

Address No. 3 Guangtong Street, Industrial Development Zone, Zhangjiawan Tongzhou District, Beijing, CHN
Beijing Luzhu Biotechnology Co., Ltd. is a biotechnology company committed to developing human vaccines and therapeutic biologics to prevent and control infectious diseases and treat cancer and autoimmune diseases. The Group's product pipeline consisted of three clinical-stage product candidates, including its Core Product, LZ901, and six pre-clinical-stage product candidates.
24GF Score

Get the complete analysis for HKSE:02480

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$13.00
Price